Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.

Biologics Nasal polyposis Severe asthma Super-response

Journal

Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875

Informations de publication

Date de publication:
15 Jul 2024
Historique:
received: 05 04 2024
accepted: 01 06 2024
medline: 15 7 2024
pubmed: 15 7 2024
entrez: 15 7 2024
Statut: aheadofprint

Résumé

Nasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics. We evaluated (super-) response in SA patients with (NP +) and without NP (NP-) enrolled in the Belgian Severe Asthma Registry (BSAR). 914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV In conclusion, both NP + and NP - patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV

Sections du résumé

BACKGROUND BACKGROUND
Nasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics.
METHODS METHODS
We evaluated (super-) response in SA patients with (NP +) and without NP (NP-) enrolled in the Belgian Severe Asthma Registry (BSAR).
RESULTS RESULTS
914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV
CONCLUSION CONCLUSIONS
In conclusion, both NP + and NP - patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV

Identifiants

DOI: 10.1007/s00408-024-00715-0 PMID: 39007944
pubmed: 39007944
doi: 10.1007/s00408-024-00715-0
pii: 10.1007/s00408-024-00715-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Canonica GW, Malvezzi L, Blasi F et al (2020) Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med 166:105947. https://doi.org/10.1016/j.rmed.2020.105947
doi: 10.1016/j.rmed.2020.105947 pubmed: 32250875
Brusselle GG, Koppelman GH (2022) Biologic therapies for severe asthma. N Engl J Med 386(2):157–171. https://doi.org/10.1056/NEJMra2032506
doi: 10.1056/NEJMra2032506 pubmed: 35020986
Schleich F, Moermans C, Seidel L et al (2023) Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction - PROMISE. ERJ Open Res 9(6):00383–02023. https://doi.org/10.1183/23120541.00383-2023
doi: 10.1183/23120541.00383-2023 pubmed: 38020567 pmcid: 10680030
Wautlet A, Bachert C, Desrosiers M, Hellings PW, Peters AT (2023) The management of chronic rhinosinusitis with nasal polyps (CRSwNP) with biologics. J Allergy Clin Immunol Pract 11(9):2642–2651. https://doi.org/10.1016/j.jaip.2023.04.054
doi: 10.1016/j.jaip.2023.04.054 pubmed: 37182568
Kolkhir P, Akdis CA, Akdis M et al (2023) Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov 22(9):743–767. https://doi.org/10.1038/s41573-023-00750-1
doi: 10.1038/s41573-023-00750-1 pubmed: 37528191
Wechsler ME, Scelo G, Larenas-Linnemann DES et al (2024) Association between T2-related comorbidities and effectiveness of biologics in severe asthma. Am J Respir Crit Care Med 209(3):262–272. https://doi.org/10.1164/rccm.202305-0808OC
doi: 10.1164/rccm.202305-0808OC pubmed: 38016003
Cottin S, Doyen V, Pilette C (2023) Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma. Front Med (Lausanne) 10:1129300. https://doi.org/10.3389/fmed.2023.1129300
doi: 10.3389/fmed.2023.1129300 pubmed: 37035303
Upham JW, Le Lievre C, Jackson DJ et al (2021) Defining a severe asthma super-responder: findings from a delphi process. J Allergy Clin Immunol Pract 9(11):3997–4004. https://doi.org/10.1016/j.jaip.2021.06.041
doi: 10.1016/j.jaip.2021.06.041 pubmed: 34271216
Kavanagh JE, d’Ancona G, Elstad M et al (2020) Real-world effectiveness and the characteristics of a “Super-Responder” to mepolizumab in severe eosinophilic asthma. Chest 158(2):491–500. https://doi.org/10.1016/j.chest.2020.03.042
doi: 10.1016/j.chest.2020.03.042 pubmed: 32275980
Gerday S, Graff S, Moermans C et al (2023) Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline. Thorax 78(11):1138–1141. https://doi.org/10.1136/thorax-2022-219781
doi: 10.1136/thorax-2022-219781 pubmed: 37657926
Global Initiative for Asthma (2023) Global Strategy for Asthma Management and Prevention. www.ginasthma.org . Accessed 5 Apr 2024.
Chung KF, Wenzel SE, Brozek JL, et al. (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Eur Respir J 43(2):343–373. https://doi.org/10.1183/09031936.00202013
Nathan RA, Sorkness CA, Kosinski M et al (2004) Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113(1):59–65. https://doi.org/10.1016/j.jaci.2003.09.008
doi: 10.1016/j.jaci.2003.09.008 pubmed: 14713908
Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR (1999) Development and validation of a questionnaire to measure asthma control. Eur Respir J 14(4):902–907. https://doi.org/10.1034/j.1399-3003.1999.14d29.x
doi: 10.1034/j.1399-3003.1999.14d29.x pubmed: 10573240
Juniper EF, Guyatt GH, Willan A, Griffith LE (1994) Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 47(1):81–87. https://doi.org/10.1016/0895-4356(94)90036-1
doi: 10.1016/0895-4356(94)90036-1 pubmed: 8283197
Maniscalco M, Calabrese C, D’Amato M et al (2019) Association between exhaled nitric oxide and nasal polyposis in severe asthma. Respir Med 152:20–24. https://doi.org/10.1016/j.rmed.2019.04.017
doi: 10.1016/j.rmed.2019.04.017 pubmed: 31128605
Gibson PG, Prazma CM, Chupp GL et al (2021) Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res 22(1):171. https://doi.org/10.1186/s12931-021-01746-4
doi: 10.1186/s12931-021-01746-4 pubmed: 34098955 pmcid: 8182929

Auteurs

Femke Demolder (F)

Respiratory Division, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), 1090, Brussels, Belgium. femke.demolder@uzbrussel.be.

Eef Vanderhelst (E)

Respiratory Division, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), 1090, Brussels, Belgium.

Sylvia Verbanck (S)

Respiratory Division, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), 1090, Brussels, Belgium.

Florence Schleich (F)

Respiratory Medicine, CHU of Liège, University of Liège, GIGA I3, 4000, Liège, Belgium.

Renaud Louis (R)

Department of Pneumology, CHU Liège and GiGAI3 Research Group University of Liège, 4000, Liège, Belgium.

Guy Brusselle (G)

Department of Respiratory Medicine, Ghent University Hospital, 9000, Ghent, Belgium.

Carine Sohy (C)

Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur (Site Godinne), Université Catholique de Louvain, Yvoir, Belgium.

Alain Michils (A)

Chest Department, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Rudi Peché (R)

CHU Charleroi Réseau Humani, ULB, Brussels, Belgium.

Charles Pilette (C)

Pneumology Department, Cliniques Universitaires Saint-Luc, and Institute of Experimental and Clinical Research (IREC), UCLouvain, 1200, Brussels, Belgium.

Shane Hanon (S)

Respiratory Division, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), 1090, Brussels, Belgium.

Classifications MeSH